Michael R. Hayden - Publications

Affiliations: 
University of British Columbia, Vancouver, Vancouver, BC, Canada 
Area:
Biostatistics Biology

308 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Caron NS, Banos R, Aly AE, Xie Y, Ko S, Potluri N, Anderson C, Black HF, Anderson LM, Gordon B, Southwell AL, Hayden MR. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice. Neurobiology of Disease. 166: 105652. PMID 35143966 DOI: 10.1016/j.nbd.2022.105652  0.743
2021 Bhattacharyya A, Trotta CR, Narasimhan J, Wiedinger KJ, Li W, Effenberger KA, Woll MG, Jani MB, Risher N, Yeh S, Cheng Y, Sydorenko N, Moon YC, Karp GM, Weetall M, ... ... Hayden M, et al. Small molecule splicing modifiers with systemic HTT-lowering activity. Nature Communications. 12: 7299. PMID 34911927 DOI: 10.1038/s41467-021-27157-z  0.735
2021 Lemarié FL, Caron NS, Sanders SS, Schmidt ME, Nguyen YTN, Ko S, Xu X, Pouladi MA, Martin DDO, Hayden MR. Rescue of aberrant huntingtin palmitoylation ameliorates mutant huntingtin-induced toxicity. Neurobiology of Disease. 105479. PMID 34390831 DOI: 10.1016/j.nbd.2021.105479  0.697
2021 Caron NS, Anderson C, Black HF, Sanders SS, Lemarié FL, Doty CN, Hayden MR. Reliable Resolution of Full-Length Huntingtin Alleles by Quantitative Immunoblotting. Journal of Huntington's Disease. PMID 34092649 DOI: 10.3233/JHD-200463  0.369
2021 Naia L, Ly P, Mota SI, Lopes C, Maranga C, Coelho P, Gershoni-Emek N, Ankarcrona M, Geva M, Hayden MR, Rego AC. The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33797036 DOI: 10.1007/s13311-021-01022-9  0.311
2021 Ravalia AS, Lau J, Barron J, Purchase S, Southwell AL, Hayden MR, Nafar F, Parsons MP. Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic Huntington disease mice. Neurobiology of Disease. 105293. PMID 33556538 DOI: 10.1016/j.nbd.2021.105293  0.736
2020 Caron NS, Banos R, Yanick C, Aly AE, Byrne LM, Smith ED, Xie Y, Smith SEP, Potluri N, Findlay Black H, Casal L, Ko S, Cheung D, Kim H, Seong IS, ... ... Hayden MR, et al. Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33310753 DOI: 10.1523/JNEUROSCI.1865-20.2020  0.743
2020 Schmidt ME, Caron NS, Aly AE, Lemarié FL, Dal Cengio L, Ko Y, Lazic N, Anderson L, Nguyen B, Raymond LA, Hayden MR. DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease. Frontiers in Cellular Neuroscience. 14: 590569. PMID 33250715 DOI: 10.3389/fncel.2020.590569  0.324
2020 Machiela E, Jeloka R, Caron NS, Mehta S, Schmidt ME, Baddeley HJE, Tom CM, Polturi N, Xie Y, Mattis VB, Hayden MR, Southwell AL. The Interaction of Aging and Cellular Stress Contributes to Pathogenesis in Mouse and Human Huntington Disease Neurons. Frontiers in Aging Neuroscience. 12: 524369. PMID 33192449 DOI: 10.3389/Fnagi.2020.524369  0.837
2020 McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW, Hayden M. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. Journal of Huntington's Disease. 9: 371-380. PMID 33164941 DOI: 10.3233/JHD-200440  0.348
2020 Wright GEB, Black HF, Collins JA, Gall-Duncan T, Caron NS, Pearson CE, Hayden MR. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies. The Lancet. Neurology. 19: 930-939. PMID 33098802 DOI: 10.1016/S1474-4422(20)30343-4  0.348
2020 Xu X, Ng B, Sim B, Radulescu CI, Yusof NABM, Goh WI, Lin S, Lim JSY, Cha Y, Kusko R, Kay C, Ratovitski T, Ross C, Hayden MR, Wright G, et al. pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model. Cell Death & Disease. 11: 809. PMID 32978366 DOI: 10.1038/s41419-020-02983-z  0.827
2020 Wright GEB, Caron NS, Ng B, Casal L, Casazza W, Xu X, Ooi J, Pouladi MA, Mostafavi S, Ross CJD, Hayden MR. Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease. Human Molecular Genetics. PMID 32898862 DOI: 10.1093/Hmg/Ddaa184  0.673
2020 Findlay Black H, Wright GEB, Collins JA, Caron N, Kay C, Xia Q, Arning L, Bijlsma EK, Squitieri F, Nguyen HP, Hayden MR. Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32741964 DOI: 10.1038/S41436-020-0917-Z  0.352
2020 Squitieri F, Mazza T, Maffi S, De Luca A, AlSalmi Q, AlHarasi S, Collins JA, Kay C, Baine-Savanhu F, Landwhermeyer BG, Sabatini U, Hayden MR. Tracing the mutated HTT and haplotype of the African ancestor who spread Huntington disease into the Middle East. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32661355 DOI: 10.1038/S41436-020-0895-1  0.374
2020 Skotte NH, Pouladi MA, Ehrnhoefer DE, Huynh K, Qiu X, Nielsen SMB, Nielsen TT, Nørremølle A, Hayden MR. Compromised IGF signaling causes caspase-6 activation in Huntington disease. Experimental Neurology. 113396. PMID 32622701 DOI: 10.1016/J.Expneurol.2020.113396  0.677
2020 Bartl S, Oueslati A, Southwell AL, Siddu A, Parth M, David LS, Maxan A, Salhat N, Burkert M, Mairhofer A, Pankevych H, Balazs K, Staffler G, Hayden MR, Cicchetti F, et al. Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease. Neurobiology of Disease. 104943. PMID 32407769 DOI: 10.1016/J.Nbd.2020.104943  0.704
2019 Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, Anderson LM, Ko S, Zhu X, van Deventer SJ, Evers MM, Konstantinova P, Hayden MR. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Research. PMID 31745548 DOI: 10.1093/Nar/Gkz976  0.739
2019 Kay C, Collins JA, Caron NS, Agostinho LA, Findlay-Black H, Casal L, Sumathipala D, Dissanayake VHW, Cornejo-Olivas M, Baine F, Krause A, Greenberg JL, Paiva CLA, Squitieri F, Hayden MR. A Comprehensive Haplotype Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. American Journal of Human Genetics. PMID 31708117 DOI: 10.1016/J.Ajhg.2019.10.011  0.36
2019 Ehrnhoefer DE, Skotte NH, Reinshagen J, Qiu X, Windshügel B, Jaishankar P, Ladha S, Petina O, Khankischpur M, Nguyen YTN, Caron NS, Razeto A, Meyer Zu Rheda M, Deng Y, Huynh KT, ... ... Hayden MR, et al. Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound. Cell Chemical Biology. PMID 31353319 DOI: 10.1016/J.Chembiol.2019.07.001  0.335
2019 Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA. Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease. Frontiers in Cellular Neuroscience. 13: 209. PMID 31156395 DOI: 10.3389/Fncel.2019.00209  0.306
2019 Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiology of Disease. PMID 31108174 DOI: 10.1016/J.Nbd.2019.05.009  0.333
2019 Wright GEB, Collins JA, Kay C, McDonald C, Dolzhenko E, Xia Q, Bečanović K, Drögemöller BI, Semaka A, Nguyen CM, Trost B, Richards F, Bijlsma EK, Squitieri F, Ross CJD, ... ... Hayden MR, et al. Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease. American Journal of Human Genetics. PMID 31104771 DOI: 10.1016/J.Ajhg.2019.04.007  0.793
2019 Ferrari Bardile C, Garcia-Miralles M, Caron NS, Rayan NA, Langley SR, Harmston N, Rondelli AM, Teo RTY, Waltl S, Anderson LM, Bae HG, Jung S, Williams A, Prabhakar S, Petretto E, ... Hayden MR, et al. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 31015293 DOI: 10.1073/Pnas.1818042116  0.83
2018 Martin DDO, Schmidt ME, Nguyen YT, Lazic N, Hayden MR. Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201701510RRR. PMID 30423259 DOI: 10.1096/Fj.201701510Rrr  0.322
2018 Garcia-Miralles M, Yusof NABM, Tan JY, Radulescu CI, Sidik H, Tan LJ, Belinson H, Zach N, Hayden MR, Pouladi MA. Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease. Molecular Neurobiology. PMID 30334188 DOI: 10.1007/S12035-018-1393-1  0.835
2018 Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, ... ... Hayden MR, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Science Translational Medicine. 10. PMID 30282695 DOI: 10.1126/Scitranslmed.Aar3959  0.737
2018 Caron NS, Dorsey ER, Hayden MR. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nature Reviews. Drug Discovery. PMID 30237454 DOI: 10.1038/Nrd.2018.133  0.371
2018 Schmidt ME, Buren C, Mackay JP, Cheung D, Dal Cengio L, Raymond LA, Hayden MR. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease. Bmc Biology. 16: 58. PMID 29945611 DOI: 10.1186/S12915-018-0526-3  0.342
2018 Martin DDO, Kay C, Collins JA, Nguyen YT, Slama RA, Hayden MR. A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease. Scientific Reports. 8: 8096. PMID 29802276 DOI: 10.1038/S41598-018-25903-W  0.385
2018 Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Molecular Neurodegeneration. 13: 25. PMID 29783994 DOI: 10.1186/S13024-018-0259-3  0.679
2018 Petrella LI, Castelhano JM, Ribeiro M, Sereno JV, Gonçalves SI, Laço MN, Hayden MR, Rego AC, Castelo-Branco M. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes. Human Molecular Genetics. PMID 29668904 DOI: 10.1093/Hmg/Ddy119  0.363
2018 Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, Skotte NH, Nguyen YTN, Vaid K, Southwell AL, Engemann S, Franciosi S, Hayden MR. Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. Acta Neuropathologica Communications. 6: 16. PMID 29510748 DOI: 10.1186/S40478-018-0518-0  0.736
2018 Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, ... ... Hayden MR, et al. The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. PMID 29460498 DOI: 10.1002/Ajmg.B.32618  0.774
2018 Bardile CF, Garcia-Miralles M, Caron N, Langley S, Teo RTY, Petretto E, Hayden MR, Pouladi MA. A43 Intrinsic mutant HTT-mediated defects in oligodendroglia cells contribute to myelin deficits and behavioural abnormalities in huntington disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.41  0.832
2018 Bartl S, Oueslati A, Southwell AL, Parth M, Salhat N, Siddu A, Burkert M, Pankevych H, David L, Villanueva EB, Xie Y, Cengio LD, Ko S, Hayden MR, Cicchetti F, et al. I09 Antibodies inhibit cell to cell transmission of mutant HTT Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.245  0.683
2018 Klein P, Karneva Z, Toonen L, Kim H, Caron N, Graaf Lvd, Buil L, Horst Gvd, Anthonijsz H, Ham Fvd, Beumer W, Hayden M, Song J, Roon-Mom Wv, Platenburg G. I01 QRX-704, a novel antisense oligonucleotide therapy, designed to prevent hd pathology while maintaining htt function Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.237  0.367
2017 Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. Jci Insight. 2. PMID 29212949 DOI: 10.1172/Jci.Insight.95665  0.558
2017 Ehrnhoefer DE, Southwell AL, Sivasubramanian M, Qiu X, Villanueva EB, Xie Y, Waltl S, Anderson L, Fazeli A, Casal L, Felczak B, Tsang M, Hayden MR. HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo. Human Molecular Genetics. PMID 29121340 DOI: 10.1093/Hmg/Ddx394  0.723
2017 Kay C, Hayden MR, Leavitt BR. Epidemiology of Huntington disease. Handbook of Clinical Neurology. 144: 31-46. PMID 28947124 DOI: 10.1016/B978-0-12-801893-4.00003-1  0.378
2017 Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Laquinimod treatment in the R6/2 mouse model. Scientific Reports. 7: 4947. PMID 28694434 DOI: 10.1038/S41598-017-04990-1  0.334
2017 Naia L, Cunha-Oliveira T, Rodrigues J, Rosenstock TR, Oliveira A, Ribeiro M, Carmo C, Oliveira-Sousa SI, Duarte AI, Hayden MR, Rego AC. Histone deacetylase inhibitors protect against pyruvate dehydrogenase dysfunction in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28123081 DOI: 10.1523/Jneurosci.2006-14.2016  0.304
2017 Southwell AL, Skotte NH, Villanueva EB, Østergaard ME, Gu X, Kordasiewicz HB, Kay C, Cheung D, Xie Y, Waltl S, Dal Cengio L, Findlay-Black H, Doty CN, Petoukhov E, Iworima D, ... ... Hayden MR, et al. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Human Molecular Genetics. PMID 28104789 DOI: 10.1093/Hmg/Ddx021  0.816
2017 Hayden MR, Kay C. Author response: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 88: 334-335. PMID 28093515 DOI: 10.1212/Wnl.0000000000003528  0.353
2016 Kay C, Tirado-Hurtado I, Cornejo-Olivas M, Collins JA, Wright G, Inca-Martinez M, Veliz-Otani D, Ketelaar ME, Slama RA, Ross CJ, Mazzetti P, Hayden MR. The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. European Journal of Human Genetics : Ejhg. PMID 28000697 DOI: 10.1038/Ejhg.2016.169  0.367
2016 Sanders SS, Parsons MP, Mui KK, Southwell AL, Franciosi S, Cheung D, Waltl S, Raymond LA, Hayden MR. Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. Bmc Biology. 14: 108. PMID 27927242 DOI: 10.1186/S12915-016-0333-7  0.655
2016 Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiology of Disease. PMID 27818324 DOI: 10.1016/J.Nbd.2016.10.006  0.328
2016 Naia L, Rosenstock TR, Oliveira AM, Oliveira-Sousa SI, Caldeira GL, Carmo C, Laço MN, Hayden MR, Oliveira CR, Rego AC. Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models. Molecular Neurobiology. PMID 27590140 DOI: 10.1007/S12035-016-0048-3  0.32
2016 Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Scientific Reports. 6: 31652. PMID 27528441 DOI: 10.1136/Jnnp-2016-314597.263  0.676
2016 Geva M, Kusko R, Soares H, Fowler K, Birnberg T, Barash S, Merenlender Wagner A, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, ... ... Hayden MR, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Human Molecular Genetics. PMID 27466197 DOI: 10.1093/Hmg/Ddw238  0.302
2016 Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, Xie Y, Anderson L, Felczak B, Waltl S, Ko S, Cheung D, Dal Cengio L, Slama R, Petoukhov E, ... ... Hayden MR, et al. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Human Molecular Genetics. PMID 27378694 DOI: 10.1093/Hmg/Ddw212  0.737
2016 Kay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N, Davidson M, Slama RA, Hayden MR. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. PMID 27335115 DOI: 10.1212/Wnl.0000000000002858  0.345
2016 Maillet A, Tan K, Chai X, Sadananda SN, Mehta A, Ooi J, Hayden MR, Pouladi MA, Ghosh S, Shim W, Brunham LR. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. Scientific Reports. 6: 25333. PMID 27142468 DOI: 10.1038/Srep25333  0.579
2016 Teo RT, Hong X, Yu-Taeger L, Huang Y, Tan LJ, Xie Y, To XV, Guo L, Rajendran R, Novati A, Calaminus C, Riess O, Hayden MR, Nguyen HP, Chuang KH, et al. Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Human Molecular Genetics. PMID 27126634 DOI: 10.1093/Hmg/Ddw122  0.641
2016 Connolly C, Magnusson-Lind A, Lu G, Wagner PK, Southwell AL, Hayden MR, Björkqvist M, Leavitt BR. Enhanced Immune Response to MMP3 stimulation in Microglia Expressing Mutant Huntingtin. Neuroscience. PMID 27033979 DOI: 10.1016/J.Neuroscience.2016.03.031  0.736
2016 Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL, Hayden MR, van Deventer SJ, Petry H, Konstantinova P. Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. Molecular Therapy. Nucleic Acids. 5: e297. PMID 27003755 DOI: 10.1038/Mtna.2016.7  0.72
2016 Riechers SP, Butland S, Deng Y, Skotte N, Ehrnhoefer DE, Russ J, Laine J, Laroche M, Pouladi MA, Wanker EE, Hayden MR, Graham RK. Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. Human Molecular Genetics. PMID 26908611 DOI: 10.1093/Hmg/Ddw036  0.794
2016 Naia L, Ribeiro M, Rodrigues J, Duarte AI, Lopes C, Rosenstock TR, Hayden MR, Rego AC. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. Neuropeptides. PMID 26876526 DOI: 10.1016/J.Npep.2016.01.009  0.322
2016 Garcia-Miralles M, Ooi J, Bardile CF, Tan LJ, George M, Drum CL, Lin RY, Hayden MR, Pouladi MA. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Experimental Neurology. PMID 26825854 DOI: 10.1016/J.Expneurol.2016.01.019  0.831
2016 Graham RK, Laroche M, Lessard-Beaudoin M, Garcia-Miralles M, Kreidy C, Yu-Tager L, Hayden MR, Nguyen HP, Pouladi MA. B42 Early olfactory behaviour deficits associated with olfactory bulb atrophy and caspase-8 activation in HD rodent models Journal of Neurology, Neurosurgery & Psychiatry. 87: A24.1-A24. DOI: 10.1136/Jnnp-2016-314597.73  0.788
2016 Miralles MG, Tan LJ, Lim M, Geva M, Hayden MR, Pouladi MA. L6 Evaluation of pridopidine in the transgenic yac128 mouse model of huntington’s disease Journal of Neurology, Neurosurgery & Psychiatry. 87: A92.1-A92. DOI: 10.1136/Jnnp-2016-314597.261  0.648
2016 Miniarikova J, Zanella I, Blits B, Evers M, Zimmer V, Spoerl A, Southwell A, Hayden M, Deventer Sv, Deglon N, Petry H, Konstantinova P. L5 Pre-clinical evaluation of aav5-mihtt gene therapy of huntington’s disease in rodents Journal of Neurology, Neurosurgery & Psychiatry. 87: A91.3-A92. DOI: 10.1136/Jnnp-2016-314597.260  0.724
2016 Kay C, Collins J, Miedzybrodzka Z, Wright G, Madore S, Gordon E, Gerry N, Fisher E, Davidson M, Slama R, Hayden M. I2 Huntington’s disease reduced penetrance alleles occur at high frequency and affect age-related increases in prevalence Journal of Neurology, Neurosurgery & Psychiatry. 87: A59.3-A60. DOI: 10.1136/Jnnp-2016-314597.167  0.363
2015 Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ. Huntington disease. Nature Reviews. Disease Primers. 1: 15005. PMID 27188817 DOI: 10.1038/nrdp.2015.5  0.367
2015 Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26201449 DOI: 10.1038/Mt.2015.128  0.73
2015 Southwell AL, Smith SE, Davis TR, Caron NS, Villanueva EB, Xie Y, Collins JA, Li Ye M, Sturrock A, Leavitt BR, Schrum AG, Hayden MR. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Scientific Reports. 5: 12166. PMID 26174131 DOI: 10.1038/Srep12166  0.728
2015 Bečanović K, Nørremølle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G, Manoharan S, Doty CN, Beck J, Lahiri N, Portales-Casamar E, Warby SC, Connolly C, ... ... Hayden MR, et al. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease. Nature Neuroscience. 18: 807-16. PMID 25938884 DOI: 10.1038/Nn.4014  0.372
2015 Stroedicke M, Bounab Y, Strempel N, Klockmeier K, Yigit S, Friedrich RP, Chaurasia G, Li S, Hesse F, Riechers SP, Russ J, Nicoletti C, Boeddrich A, Wiglenda T, Haenig C, ... ... Hayden MR, et al. Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Research. 25: 701-13. PMID 25908449 DOI: 10.1101/Gr.182444.114  0.701
2015 Sanders SS, Hayden MR. Aberrant palmitoylation in Huntington disease. Biochemical Society Transactions. 43: 205-10. PMID 25849918 DOI: 10.1042/Bst20140242  0.391
2015 Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, Mandefro B, Sareen D, Arjomand J, Hayden MR, Ross CA, et al. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Human Molecular Genetics. 24: 3257-71. PMID 25740845 DOI: 10.1093/Hmg/Ddv080  0.731
2015 Sturrock A, Laule C, Wyper K, Milner RA, Decolongon J, Dar Santos R, Coleman AJ, Carter K, Creighton S, Bechtel N, Bohlen S, Reilmann R, Johnson HJ, Hayden MR, Tabrizi SJ, et al. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 393-401. PMID 25690257 DOI: 10.1002/Mds.26118  0.358
2015 Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, ... ... Hayden MR, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 76: 46-56. PMID 25662335 DOI: 10.1016/J.Nbd.2015.01.002  0.806
2015 Østergaard ME, Thomas G, Koller E, Southwell AL, Hayden MR, Seth PP. Biophysical and biological characterization of hairpin and molecular beacon RNase H active antisense oligonucleotides. Acs Chemical Biology. 10: 1227-33. PMID 25654188 DOI: 10.1021/Cb500880F  0.641
2015 Aharony I, Ehrnhoefer DE, Shruster A, Qiu X, Franciosi S, Hayden MR, Offen D. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Human Molecular Genetics. 24: 2604-14. PMID 25616965 DOI: 10.1093/Hmg/Ddv023  0.302
2015 Wong BK, Ehrnhoefer DE, Graham RK, Martin DD, Ladha S, Uribe V, Stanek LM, Franciosi S, Qiu X, Deng Y, Kovalik V, Zhang W, Pouladi MA, Shihabuddin LS, Hayden MR. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiology of Disease. 76: 24-36. PMID 25583186 DOI: 10.1016/J.Nbd.2014.12.030  0.81
2015 Sanders SS, Hou J, Sutton LM, Garside VC, Mui KK, Singaraja RR, Hayden MR, Hoodless PA. Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development. Developmental Biology. 397: 257-66. PMID 25478910 DOI: 10.1016/J.Ydbio.2014.11.018  0.384
2015 Semaka A, Kay C, Belfroid RD, Bijlsma EK, Losekoot M, van Langen IM, van Maarle MC, Oosterloo M, Hayden MR, van Belzen MJ. A new mutation for Huntington disease following maternal transmission of an intermediate allele. European Journal of Medical Genetics. 58: 28-30. PMID 25464109 DOI: 10.1016/J.Ejmg.2014.11.005  0.787
2015 Ooi J, Hayden MR, Pouladi MA. Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. Molecular Neurobiology. 52: 1850-61. PMID 25398695 DOI: 10.1007/S12035-014-8974-4  0.657
2015 Martin DD, Ladha S, Ehrnhoefer DE, Hayden MR. Autophagy in Huntington disease and huntingtin in autophagy. Trends in Neurosciences. 38: 26-35. PMID 25282404 DOI: 10.1016/J.Tins.2014.09.003  0.35
2015 Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry Molecular Therapy. DOI: 10.1038/mt.2015.128  0.628
2015 Southwell AL, Skotte NH, Caron N, Kordasiewicz H, Oestergaard M, Doty CN, Villanueva EB, Xie Y, Felczak B, Freier SM, Swayze EE, Seth PP, Frank Bennet C, Hayden MR. 696. Pre-Clinical Evaluation of Allele-Specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides Molecular Therapy. 23: S277. DOI: 10.1016/S1525-0016(16)34305-2  0.74
2014 Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, ... Hayden MR, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. Plos One. 9: e107434. PMID 25207939 DOI: 10.1371/Journal.Pone.0107434  0.844
2014 Southwell AL, Skotte NH, Kordasiewicz HB, Østergaard ME, Watt AT, Carroll JB, Doty CN, Villanueva EB, Petoukhov E, Vaid K, Xie Y, Freier SM, Swayze EE, Seth PP, Bennett CF, ... Hayden MR, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2093-106. PMID 25101598 DOI: 10.1038/Mt.2014.153  0.844
2014 Kolodziejczyk K, Parsons MP, Southwell AL, Hayden MR, Raymond LA. Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease. Plos One. 9: e94562. PMID 24728353 DOI: 10.1371/Journal.Pone.0094562  0.733
2014 Butland SL, Sanders SS, Schmidt ME, Riechers SP, Lin DT, Martin DD, Vaid K, Graham RK, Singaraja RR, Wanker EE, Conibear E, Hayden MR. The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's disease. Human Molecular Genetics. 23: 4142-60. PMID 24705354 DOI: 10.1093/Hmg/Ddu137  0.71
2014 Sanders SS, Mui KK, Sutton LM, Hayden MR. Identification of binding sites in Huntingtin for the Huntingtin Interacting Proteins HIP14 and HIP14L. Plos One. 9: e90669. PMID 24651384 DOI: 10.1371/Journal.Pone.0090669  0.313
2014 Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. Clinical Genetics. 86: 29-36. PMID 24646433 DOI: 10.1111/Cge.12385  0.729
2014 Rotblat B, Southwell AL, Ehrnhoefer DE, Skotte NH, Metzler M, Franciosi S, Leprivier G, Somasekharan SP, Barokas A, Deng Y, Tang T, Mathers J, Cetinbas N, Daugaard M, Kwok B, ... ... Hayden MR, et al. HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proceedings of the National Academy of Sciences of the United States of America. 111: 3032-7. PMID 24516159 DOI: 10.1073/Pnas.1314421111  0.658
2014 Martin DD, Heit RJ, Yap MC, Davidson MW, Hayden MR, Berthiaume LG. Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin. Human Molecular Genetics. 23: 3166-79. PMID 24459296 DOI: 10.1093/Hmg/Ddu027  0.352
2014 Lopes C, Ribeiro M, Duarte AI, Humbert S, Saudou F, Pereira de Almeida L, Hayden M, Rego AC. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. Molecular Neurobiology. 49: 1126-42. PMID 24347322 DOI: 10.1007/S12035-013-8585-5  0.351
2014 Parsons MP, Kang R, Buren C, Dau A, Southwell AL, Doty CN, Sanders SS, Hayden MR, Raymond LA. Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin. The Journal of Biological Chemistry. 289: 3518-28. PMID 24347167 DOI: 10.1074/Jbc.M113.513945  0.686
2014 Semaka A, Hayden MR. Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results Clinical Genetics. 85: 303-311. PMID 24256063 DOI: 10.1111/Cge.12324  0.785
2014 Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 105-14. PMID 24151181 DOI: 10.1002/Mds.25717  0.352
2014 Ehrnhoefer DE, Skotte NH, Ladha S, Nguyen YT, Qiu X, Deng Y, Huynh KT, Engemann S, Nielsen SM, Becanovic K, Leavitt BR, Hasholt L, Hayden MR. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Human Molecular Genetics. 23: 717-29. PMID 24070868 DOI: 10.1093/Hmg/Ddt458  0.303
2014 Kay C, Collins J, Skotte N, Southwell A, DiPardo A, Ross C, Squitieri F, Hayden M. M03 Complete Huntingtin Haplotypes For Allele-specific Silencing Journal of Neurology, Neurosurgery & Psychiatry. 85: A95-A95. DOI: 10.1136/Jnnp-2014-309032.275  0.732
2013 Stanek LM, Yang W, Angus S, Sardi PS, Hayden MR, Hung GH, Bennett CF, Cheng SH, Shihabuddin LS. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. Journal of Huntington's Disease. 2: 217-28. PMID 25063516 DOI: 10.3233/Jhd-130057  0.387
2013 Wan J, Savas JN, Roth AF, Sanders SS, Singaraja RR, Hayden MR, Yates JR, Davis NG. Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease. Chemistry & Biology. 20: 1421-34. PMID 24211138 DOI: 10.1016/J.Chembiol.2013.09.018  0.37
2013 Franciosi S, Shim Y, Lau M, Hayden MR, Leavitt BR. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1987-94. PMID 24142393 DOI: 10.1002/Mds.25663  0.365
2013 Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nature Reviews. Neuroscience. 14: 708-21. PMID 24052178 DOI: 10.1038/Nrn3570  0.672
2013 Semaka A, Kay C, Doty CN, Collins JA, Tam N, Hayden MR. High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 162: 864-71. PMID 24038799 DOI: 10.1002/Ajmg.B.32193  0.783
2013 Østergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN, Vaid K, Villanueva EB, Swayze EE, Bennett CF, Hayden MR, Seth PP. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS Nucleic Acids Research. 41: 9634-9650. PMID 23963702 DOI: 10.1093/Nar/Gkt725  0.715
2013 Houge G, Bruland O, Bjørnevoll I, Hayden MR, Semaka A. De novo Huntington disease caused by 26-44 CAG repeat expansion on a low-risk haplotype. Neurology. 81: 1099-100. PMID 23946314 DOI: 10.1212/Wnl.0B013E3182A4A4Af  0.779
2013 Semaka A, Kay C, Doty C, Collins JA, Bijlsma EK, Richards F, Goldberg YP, Hayden MR. CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. Journal of Medical Genetics. 50: 696-703. PMID 23896435 DOI: 10.1136/Jmedgenet-2013-101796  0.788
2013 Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, et al. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nature Medicine. 19: 1030-8. PMID 23852340 DOI: 10.1038/Nm.3246  0.795
2013 Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, et al. Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics. 14: 173-9. PMID 23644918 DOI: 10.1007/S10048-013-0364-Y  0.351
2013 Baine FK, Kay C, Ketelaar ME, Collins JA, Semaka A, Doty CN, Krause A, Greenberg LJ, Hayden MR. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. European Journal of Human Genetics : Ejhg. 21: 1120-7. PMID 23463025 DOI: 10.1038/Ejhg.2013.2  0.788
2013 Sutton LM, Sanders SS, Butland SL, Singaraja RR, Franciosi S, Southwell AL, Doty CN, Schmidt ME, Mui KK, Kovalik V, Young FB, Zhang W, Hayden MR. Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease. Human Molecular Genetics. 22: 452-65. PMID 23077216 DOI: 10.1093/Hmg/Dds441  0.741
2013 Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, Villanueva EB, Kovalik V, Xie Y, Pouladi MA, Collins JA, Yang XW, Franciosi S, Hayden MR. A fully humanized transgenic mouse model of Huntington disease. Human Molecular Genetics. 22: 18-34. PMID 23001568 DOI: 10.1093/Hmg/Dds397  0.845
2013 Semaka A, Balneaves LG, Hayden MR. "Grasping the grey": Patient understanding and interpretation of an intermediate allele predictive test result for huntington disease Journal of Genetic Counseling. 22: 200-217. PMID 22903792 DOI: 10.1007/S10897-012-9533-7  0.774
2012 Graham RK, Deng Y, Pouladi MA, Vaid K, Ehrnhoefer D, Southwell AL, Bissada N, Franciosi S, Hayden MR. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. Journal of Huntington's Disease. 1: 243-60. PMID 25063333 DOI: 10.3233/Jhd-120038  0.839
2012 Strong MK, Southwell AL, Yonan JM, Hayden MR, Macgregor GR, Thompson LM, Steward O. Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. Journal of Huntington's Disease. 1: 221-41. PMID 23833693 DOI: 10.3233/Jhd-129005  0.708
2012 Southwell AL, Skotte NH, Bennett CF, Hayden MR. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine. 18: 634-43. PMID 23026741 DOI: 10.1016/J.Molmed.2012.09.001  0.676
2012 Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, et al. Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Human Genetics. 131: 1833-40. PMID 22825315 DOI: 10.1007/S00439-012-1205-Z  0.329
2012 Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Néri C, Hayden MR. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 48: 282-9. PMID 22796360 DOI: 10.1016/J.Nbd.2012.06.026  0.806
2012 Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, et al. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochemical and Biophysical Research Communications. 424: 404-8. PMID 22771793 DOI: 10.1016/J.Bbrc.2012.06.120  0.325
2012 Pouladi MA, Hayden MR. Polyglutamine diseases and the risk of cancer. The Lancet. Oncology. 13: 569-71. PMID 22652230 DOI: 10.1016/S1470-2045(12)70167-5  0.558
2012 Young FB, Franciosi S, Spreeuw A, Deng Y, Sanders S, Tam NC, Huang K, Singaraja RR, Zhang W, Bissada N, Kay C, Hayden MR. Low levels of human HIP14 are sufficient to rescue neuropathological, behavioural, and enzymatic defects due to loss of murine HIP14 in Hip14-/- mice. Plos One. 7: e36315. PMID 22649491 DOI: 10.1371/Journal.Pone.0036315  0.357
2012 Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Griguoli A, Di Donato S, Gomez-Tortosa E, Ayuso C, et al. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. American Journal of Human Genetics. 90: 434-44. PMID 22387017 DOI: 10.1016/J.Ajhg.2012.01.005  0.338
2012 Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W, Cheng SH, Shihabuddin LS, Hayden MR. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Human Molecular Genetics. 21: 2219-32. PMID 22328089 DOI: 10.1093/Hmg/Dds037  0.81
2012 Uribe V, Wong BK, Graham RK, Cusack CL, Skotte NH, Pouladi MA, Xie Y, Feinberg K, Ou Y, Ouyang Y, Deng Y, Franciosi S, Bissada N, Spreeuw A, Zhang W, ... ... Hayden MR, et al. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Human Molecular Genetics. 21: 1954-67. PMID 22262731 DOI: 10.1093/Hmg/Dds005  0.775
2012 Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, Arbez N, Graham RK, Hayden MR, Hou Z, Mori S, Swing D, Pletnikov M, Duan W, Tessarollo L, Ross CA. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 183-93. PMID 22219281 DOI: 10.1523/Jneurosci.1305-11.2012  0.707
2012 Young FB, Butland SL, Sanders SS, Sutton LM, Hayden MR. Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases. Progress in Neurobiology. 97: 220-38. PMID 22155432 DOI: 10.1016/J.Pneurobio.2011.11.002  0.377
2012 Franciosi S, Ryu JK, Shim Y, Hill A, Connolly C, Hayden MR, McLarnon JG, Leavitt BR. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 45: 438-49. PMID 21946335 DOI: 10.1016/J.Nbd.2011.09.003  0.331
2012 Bombard Y, Semaka A, Hayden MR. Adoption and the communication of genetic risk: Experiences in Huntington disease Clinical Genetics. 81: 64-69. PMID 21204796 DOI: 10.1111/J.1399-0004.2010.01614.X  0.746
2011 Graham RK, Ehrnhoefer DE, Hayden MR. Caspase-6 and neurodegeneration. Trends in Neurosciences. 34: 646-56. PMID 22018804 DOI: 10.1016/J.Tins.2011.09.001  0.609
2011 Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 2178-85. PMID 21971427 DOI: 10.1038/Mt.2011.201  0.844
2011 Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease Nature Reviews Neurology. 7: 561-572. PMID 21894212 DOI: 10.1038/Nrneurol.2011.132  0.332
2011 Carroll JB, Southwell AL, Graham RK, Lerch JP, Ehrnhoefer DE, Cao LP, Zhang WN, Deng Y, Bissada N, Henkelman RM, Hayden MR. Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Molecular Neurodegeneration. 6: 59. PMID 21854568 DOI: 10.1186/1750-1326-6-59  0.841
2011 Singaraja RR, Huang K, Sanders SS, Milnerwood AJ, Hines R, Lerch JP, Franciosi S, Drisdel RC, Vaid K, Young FB, Doty C, Wan J, Bissada N, Henkelman RM, Green WN, ... ... Hayden MR, et al. Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Human Molecular Genetics. 20: 3899-909. PMID 21775500 DOI: 10.1093/Hmg/Ddr308  0.382
2011 Huang K, Sanders SS, Kang R, Carroll JB, Sutton L, Wan J, Singaraja R, Young FB, Liu L, El-Husseini A, Davis NG, Hayden MR. Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14. Human Molecular Genetics. 20: 3356-65. PMID 21636527 DOI: 10.1093/Hmg/Ddr242  0.773
2011 Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiology of Disease. 43: 257-65. PMID 21458571 DOI: 10.1016/J.Nbd.2011.03.018  0.76
2011 Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, Pouladi MA, Hayden MR, Masliah E, Ellisman M, Rouiller I, Schwarzenbacher R, Bossy B, et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nature Medicine. 17: 377-82. PMID 21336284 DOI: 10.1038/Nm.2313  0.659
2011 Ehrnhoefer DE, Sutton L, Hayden MR. Small changes, big impact: Posttranslational modifications and function of huntingtin in huntington disease Neuroscientist. 17: 475-492. PMID 21311053 DOI: 10.1177/1073858410390378  0.377
2011 Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, Hayden AR, Kanazawa I, Ross CJ, Hayden MR. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. European Journal of Human Genetics : Ejhg. 19: 561-6. PMID 21248742 DOI: 10.1038/Ejhg.2010.229  0.354
2011 Simpson JM, Gil-Mohapel J, Pouladi MA, Ghilan M, Xie Y, Hayden MR, Christie BR. Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiology of Disease. 41: 249-60. PMID 20875859 DOI: 10.1016/J.Nbd.2010.09.012  0.619
2011 Petrilli⁎ AM, Song W, Bossy B, Liot G, Lubitz S, de Assis V, Johnson J, Poquiz P, Tjong J, Pouladi M, Hayden MR, Masliah E, Ellisman M, Rouiller I, Perkins G, et al. Mutant Huntington interaction with DRP1 impairs the mitochondrial fission and fusion balance and mediates neuronal injury Mitochondrion. 11: 649. DOI: 10.1016/J.Mito.2011.03.045  0.558
2010 Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi MA, Metzler M, Bissada N, Wang L, Faull RL, Gray M, Yang XW, Raymond LA, Hayden MR. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 15019-29. PMID 21068307 DOI: 10.1523/Jneurosci.2071-10.2010  0.801
2010 Sturrock A, Laule C, Decolongon J, Dar Santos R, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 75: 1702-10. PMID 21060093 DOI: 10.1212/Wnl.0B013E3181Fc27E4  0.363
2010 Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, Lu G, Leavitt BR, Hayden MR. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 14318-29. PMID 20980587 DOI: 10.1523/Jneurosci.1589-10.2010  0.707
2010 Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O, MacDonald M, Wellington C, DiDonato S, Hayden M, Cattaneo E. Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 10844-50. PMID 20702713 DOI: 10.1523/Jneurosci.0917-10.2010  0.815
2010 Huang K, Kang MH, Askew C, Kang R, Sanders SS, Wan J, Davis NG, Hayden MR. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 40: 207-15. PMID 20685337 DOI: 10.1016/J.Nbd.2010.05.027  0.317
2010 Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 65: 178-90. PMID 20152125 DOI: 10.1016/J.Neuron.2010.01.008  0.792
2010 Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Human Molecular Genetics. 19: 1528-38. PMID 20097678 DOI: 10.1093/Hmg/Ddq026  0.771
2010 Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R, Hayden MR, Leavitt BR. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Human Molecular Genetics. 19: 1438-52. PMID 20089533 DOI: 10.1093/Hmg/Ddq018  0.651
2010 Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 397-408. PMID 19548255 DOI: 10.1002/Ajmg.B.30992  0.303
2010 Semaka A, Collins JA, Hayden MR. Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles). American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 314-20. PMID 19455596 DOI: 10.1002/Ajmg.B.30970  0.79
2010 Sturrock A, Laule C, Decolongon J, dar Santos R, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. H06 Cross sectional and longitudinal 3T magnetic resonance spectroscopy in a TRACK-HD cohort of individuals with premanifest and early Huntington's disease Journal of Neurology, Neurosurgery & Psychiatry. 81: A35.2-A35. DOI: 10.1136/Jnnp.2010.222653.6  0.363
2010 Pouladi MA, Brilluad E, Xie Y, Franciosi S, Zhang W, Zapala M, Compte E, Poucheret P, Maurel J, Néri C, Hayden MR. B13 NP03, a low dose lithium microemulsion, improves motor function and rescues striatal pathology without toxicity in the YAC128 mouse model of Huntington's disease Journal of Neurology, Neurosurgery & Psychiatry. 81: A15.1-A15. DOI: 10.1136/Jnnp.2010.222596.13  0.666
2010 Pouladi MA, Carroll J, dar Santos R, Bertram L, Hayden MR. B12 Treatment with arimoclomol does not lead to rescue of motor or striatal deficits in the YAC128 mouse model of Huntington's disease Journal of Neurology, Neurosurgery & Psychiatry. 81: A14.2-A14. DOI: 10.1136/Jnnp.2010.222596.12  0.821
2010 Graham RK, Deng Y, Pouladi MA, Vaid K, Xie Y, Bissada N, Franciosi S, Hayden MR. A04 Caspase 6 resistant mutant huntingtin does not rescue the toxic effects of caspase cleavable mutant huntingtin in vivo Journal of Neurology, Neurosurgery & Psychiatry. 81: A2.1-A2. DOI: 10.1136/Jnnp.2010.222570.4  0.805
2010 Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RWY, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice (DOI:10.1016/j.neuron.2010.01.008) Neuron. 65: 436. DOI: 10.1016/j.neuron.2010.01.031  0.722
2009 Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. The Journal of Cell Biology. 187: 1083-99. PMID 20026656 DOI: 10.1083/Jcb.200909067  0.576
2009 Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Medicine. 15: 1407-13. PMID 19915593 DOI: 10.1038/Nm.2056  0.769
2009 Fan J, Cowan CM, Zhang LY, Hayden MR, Raymond LA. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 10928-38. PMID 19726651 DOI: 10.1523/Jneurosci.2491-09.2009  0.329
2009 Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR. Mouse models of Huntington disease: Variations on a theme Dmm Disease Models and Mechanisms. 2: 123-129. PMID 19259385 DOI: 10.1242/Dmm.002451  0.658
2009 Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. American Journal of Human Genetics. 84: 351-66. PMID 19249009 DOI: 10.1016/J.Ajhg.2009.02.003  0.84
2009 Joshi PR, Wu NP, André VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2414-27. PMID 19244517 DOI: 10.1523/Jneurosci.5687-08.2009  0.745
2009 Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, André VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2193-204. PMID 19228972 DOI: 10.1523/Jneurosci.5473-08.2009  0.843
2009 Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain : a Journal of Neurology. 132: 919-32. PMID 19224899 DOI: 10.1093/Brain/Awp006  0.774
2009 Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, D'Ambola J, Hou Z, Liang Y, Poirier MA, Hirschhorn RR, Graham R, Hayden MR, Cole RN, Ross CA. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. The Journal of Biological Chemistry. 284: 10855-67. PMID 19204007 DOI: 10.1074/Jbc.M804813200  0.678
2009 MacDonald ML, van Eck M, Hildebrand RB, Wong BW, Bissada N, Ruddle P, Kontush A, Hussein H, Pouladi MA, Chapman MJ, Fievet C, van Berkel TJ, Staels B, McManus BM, Hayden MR. Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 29: 341-7. PMID 19095997 DOI: 10.1161/Atvbaha.108.181099  0.57
2009 Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Molecular and Cellular Neurosciences. 40: 121-7. PMID 18992820 DOI: 10.1016/J.Mcn.2008.09.007  0.706
2009 Gil-Mohapel J, Simpson J, Pouladi M, Hayden M, Christie B. Evaluation of Hippocampal Neurogenesis in YAC128 Huntington’s Disease Transgenic Mice European Psychiatry. 24: 1-1. DOI: 10.1016/S0924-9338(09)71153-8  0.558
2008 Cowan CM, Fan MM, Fan J, Shehadeh J, Zhang LY, Graham RK, Hayden MR, Raymond LA. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 12725-35. PMID 19036965 DOI: 10.1523/Jneurosci.4619-08.2008  0.689
2008 Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of Experimental Medicine. 205: 1869-77. PMID 18625748 DOI: 10.1084/Jem.20080178  0.685
2008 Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, Hayden MR, Li S, Chan AW, Li XJ. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Human Molecular Genetics. 17: 2738-51. PMID 18558632 DOI: 10.1093/Hmg/Ddn175  0.714
2008 Semaka A, Warby S, Leavitt BR, Hayden MR. Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1794-5; author reply. PMID 18548612 DOI: 10.1002/mds.21820  0.705
2008 Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiology of Disease. 31: 80-8. PMID 18502655 DOI: 10.1016/J.Nbd.2008.03.010  0.835
2008 Warby SC, Doty CN, Graham RK, Carroll JB, Yang YZ, Singaraja RR, Overall CM, Hayden MR. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Human Molecular Genetics. 17: 2390-404. PMID 18445618 DOI: 10.1093/Hmg/Ddn139  0.82
2008 Lerch JP, Carroll JB, Dorr A, Spring S, Evans AC, Hayden MR, Sled JG, Henkelman RM. Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. Neuroimage. 41: 243-51. PMID 18387826 DOI: 10.1016/J.Neuroimage.2008.02.019  0.73
2008 Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, ... Hayden M, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery, and Psychiatry. 79: 874-80. PMID 18096682 DOI: 10.1136/Jnnp.2007.128728  0.369
2008 Fan MM, Zhang H, Hayden MR, Pelech SL, Raymond LA. Protective up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA receptors. Journal of Neurochemistry. 104: 790-805. PMID 17971125 DOI: 10.1111/J.1471-4159.2007.05016.X  0.302
2008 Bombard Y, Penziner E, Suchowersky O, Guttman M, Paulsen JS, Bottorff JL, Hayden MR. Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. European Journal of Human Genetics : Ejhg. 16: 279-89. PMID 17957229 DOI: 10.1038/Sj.Ejhg.5201937  0.303
2008 Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Henkelman RM. Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage. 39: 32-9. PMID 17942324 DOI: 10.1016/J.Neuroimage.2007.08.033  0.75
2008 Wild EJ, Björkqvist M, Thiele J, Silvestroni A, Soulet D, Magnusson A, Benn CL, Woodman B, André R, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, et al. P3-377: A novel pathogenic pathway of immune activation detectable before cinical onset in Huntington's disease Alzheimer's & Dementia. 4: T632-T632. DOI: 10.1016/J.Jalz.2008.05.1947  0.558
2007 Ratovitski T, Nakamura M, D'Ambola J, Chighladze E, Liang Y, Wang W, Graham R, Hayden MR, Borchelt DR, Hirschhorn RR, Ross CA. N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle (Georgetown, Tex.). 6: 2970-81. PMID 18156806 DOI: 10.4161/Cc.6.23.4992  0.678
2007 Valenza M, Carroll JB, Leoni V, Bertram LN, Björkhem I, Singaraja RR, Di Donato S, Lutjohann D, Hayden MR, Cattaneo E. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Human Molecular Genetics. 16: 2187-98. PMID 17613541 DOI: 10.1093/Hmg/Ddm170  0.774
2007 Benn CL, Slow EJ, Farrell LA, Graham R, Deng Y, Hayden MR, Cha JH. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience. 147: 354-72. PMID 17544587 DOI: 10.1016/J.Neuroscience.2007.03.010  0.791
2007 Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/Hmg/Ddm133  0.692
2007 Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersén A, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, Vogl AW, Hayden MR, Leavitt BR. Testicular degeneration in Huntington disease. Neurobiology of Disease. 26: 512-20. PMID 17433700 DOI: 10.1016/J.Nbd.2007.01.006  0.388
2007 Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 3768-79. PMID 17409241 DOI: 10.1523/Jneurosci.4356-06.2007  0.345
2007 Van Raamsdonk JM, Warby SC, Hayden MR. Selective degeneration in YAC mouse models of Huntington disease Brain Research Bulletin. 72: 124-131. PMID 17352936 DOI: 10.1016/J.Brainresbull.2006.10.018  0.381
2007 Bombard Y, Penziner E, Decolongon J, Klimek ML, Creighton S, Suchowersky O, Guttman M, Paulsen JS, Bottorff JL, Hayden MR. Managing genetic discrimination: strategies used by individuals found to have the Huntington disease mutation. Clinical Genetics. 71: 220-31. PMID 17309644 DOI: 10.1111/J.1399-0004.2007.00770.X  0.308
2007 Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, Ross CA, Beglinger L, Hayden MR, Kieburtz K, Kayson E, Julian-Baros E, Duff K, Guttman M, Nance M, et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia. 45: 1767-76. PMID 17303196 DOI: 10.1016/J.Neuropsychologia.2006.12.015  0.329
2007 Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiology of Disease. 26: 189-200. PMID 17276692 DOI: 10.1016/J.Nbd.2006.12.010  0.818
2006 Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. Bmc Neuroscience. 7: 80. PMID 17147801 DOI: 10.1186/1471-2202-7-80  0.753
2006 Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, Hayden MR, Friedlander RM. Huntingtin inhibits caspase-3 activation. The Embo Journal. 25: 5896-906. PMID 17124493 DOI: 10.1038/Sj.Emboj.7601445  0.739
2006 Semaka A, Creighton S, Warby S, Hayden MR. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clinical Genetics. 70: 283-94. PMID 16965319 DOI: 10.1111/J.1399-0004.2006.00668.X  0.705
2006 Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M, Ross CA, Margolis RL, Rosenblatt A, Squitieri F, Frati L, Gómez-Tortosa E, García CA, Suchowersky O, Klimek ML, et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. Bmc Medical Genetics. 7: 71. PMID 16914060 DOI: 10.1186/1471-2350-7-71  0.321
2006 Slow EJ, Graham RK, Hayden MR. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends in Genetics : Tig. 22: 408-11. PMID 16806565 DOI: 10.1016/J.Tig.2006.05.008  0.803
2006 Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, ... ... Hayden MR, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 125: 1179-91. PMID 16777606 DOI: 10.1016/J.Cell.2006.04.026  0.836
2006 Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E. Preparing for preventive clinical trials: the Predict-HD study. Archives of Neurology. 63: 883-90. PMID 16769871 DOI: 10.1001/Archneur.63.6.883  0.361
2006 Yanai A, Huang K, Kang R, Singaraja RR, Arstikaitis P, Gan L, Orban PC, Mullard A, Cowan CM, Raymond LA, Drisdel RC, Green WN, Ravikumar B, Rubinsztein DC, El-Husseini A, ... Hayden MR, et al. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nature Neuroscience. 9: 824-31. PMID 16699508 DOI: 10.1038/Nn1702  0.356
2006 Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease. 23: 190-7. PMID 16697652 DOI: 10.1016/J.Nbd.2006.02.011  0.839
2006 Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR. Body weight is modulated by levels of full-length huntingtin. Human Molecular Genetics. 15: 1513-23. PMID 16571604 DOI: 10.1093/Hmg/Ddl072  0.736
2006 Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR. Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry. 96: 1121-9. PMID 16417581 DOI: 10.1111/J.1471-4159.2005.03605.X  0.822
2006 Graham RK, Slow EJ, Deng Y, Bissada N, Lu G, Pearson J, Shehadeh J, Leavitt BR, Raymond LA, Hayden MR. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiology of Disease. 21: 444-55. PMID 16230019 DOI: 10.1016/J.Nbd.2005.08.007  0.848
2006 Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiology of Disease. 21: 392-403. PMID 16165367 DOI: 10.1016/J.Nbd.2005.08.001  0.697
2006 Pouladi MA, Bezprozvanny I, Raymond LA, Hayden MR. Molecular pathogenesis of Huntington's disease: The role of excitotoxicity Genetic Instabilities and Neurological Diseases, Second Edition. 251-260. DOI: 10.1016/B978-012369462-1/50016-8  0.558
2005 Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 3823-35. PMID 16278236 DOI: 10.1093/Hmg/Ddi407  0.834
2005 Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry. 95: 210-20. PMID 16181425 DOI: 10.1111/J.1471-4159.2005.03357.X  0.764
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology. 196: 266-72. PMID 16129433 DOI: 10.1016/J.Expneurol.2005.07.021  0.353
2005 Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proceedings of the National Academy of Sciences of the United States of America. 102: 11402-7. PMID 16076956 DOI: 10.1073/Pnas.0503634102  0.832
2005 Pinto JT, Van Raamsdonk JM, Leavitt BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJ. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. Journal of Neurochemistry. 94: 1087-101. PMID 15992377 DOI: 10.1111/J.1471-4159.2005.03255.X  0.742
2005 Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 4169-80. PMID 15843620 DOI: 10.1523/Jneurosci.0590-05.2005  0.817
2005 Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, Crocker SF, Robertson HA, Hayden MR. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Human Molecular Genetics. 14: 1569-77. PMID 15843398 DOI: 10.1093/Hmg/Ddi165  0.361
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 1379-92. PMID 15829505 DOI: 10.1093/Hmg/Ddi147  0.759
2005 Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinás R, Kristal BS, Hayden MR, Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 102: 2602-7. PMID 15695335 DOI: 10.1073/Pnas.0409402102  0.749
2005 Van Raamsdonk JM, Hayden MR, Leavitt BR. Experimental models of Huntington's disease Drug Discovery Today: Disease Models. 2: 291-297. DOI: 10.1016/J.Ddmod.2005.11.010  0.369
2004 Margolis RL, Holmes SE, Rosenblatt A, Gourley L, O'Hearn E, Ross CA, Seltzer WK, Walker RH, Ashizawa T, Rasmussen A, Hayden M, Almqvist EW, Harris J, Fahn S, MacDonald ME, et al. Huntington's Disease-like 2 (HDL2) in North America and Japan. Annals of Neurology. 56: 670-4. PMID 15468075 DOI: 10.1002/Ana.20248  0.372
2004 Tang TS, Tu H, Orban PC, Chan EY, Hayden MR, Bezprozvanny I. HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca release in primary culture of striatal medium spiny neurons. The European Journal of Neuroscience. 20: 1779-87. PMID 15379999 DOI: 10.1111/J.1460-9568.2004.03633.X  0.321
2004 Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochemical and Biophysical Research Communications. 322: 1310-7. PMID 15336977 DOI: 10.1016/J.Bbrc.2004.08.035  0.359
2004 Li L, Murphy TH, Hayden MR, Raymond LA. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. Journal of Neurophysiology. 92: 2738-46. PMID 15240759 DOI: 10.1152/Jn.00308.2004  0.304
2004 Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES, Steinberg MH, Nolan V, Baldwin CT, Hotchkiss RS, Buchman TG, Zehnbauer BA, Hayden MR, Farrer LA, Roy S, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature. 429: 75-9. PMID 15129283 DOI: 10.1038/Nature02451  0.604
2004 Lafreniere RG, MacDonald ML, Dube MP, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio AM, ... ... Hayden MR, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics. 74: 1064-73. PMID 15060842 DOI: 10.1086/420795  0.532
2004 Harper PS, Gevers S, de Wert G, Creighton S, Bombard Y, Hayden MR. Genetic testing and Huntington's disease: issues of employment. The Lancet. Neurology. 3: 249-52. PMID 15039038 DOI: 10.1016/S1474-4422(04)00711-2  0.36
2004 Djoussé L, Knowlton B, Hayden MR, Almqvist EW, Brinkman RR, Ross CA, Margolis RL, Rosenblatt A, Durr A, Dode C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, McCusker E, et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics. 5: 109-14. PMID 15029481 DOI: 10.1007/S10048-004-0175-2  0.659
2004 Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics. 65: 267-77. PMID 15025718 DOI: 10.1111/J.1399-0004.2004.00241.X  0.648
2004 Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. The Journal of Biological Chemistry. 279: 20211-20. PMID 14981075 DOI: 10.1074/Jbc.M401267200  0.387
2004 Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, Kegel KB, Aronin N, DiFiglia M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 269-81. PMID 14715959 DOI: 10.1523/Jneurosci.1409-03.2004  0.331
2004 Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, ... Hayden MR, et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death and Differentiation. 11: 424-38. PMID 14713958 DOI: 10.1038/Sj.Cdd.4401358  0.327
2003 Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR, Murphy TH, Raymond LA. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiology of Aging. 24: 1113-21. PMID 14643383 DOI: 10.1016/J.Neurobiolaging.2003.04.003  0.331
2003 Almqvist EW, Brinkman RR, Wiggins S, Hayden MR. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clinical Genetics. 64: 300-9. PMID 12974735 DOI: 10.1034/J.1399-0004.2003.00157.X  0.583
2003 Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO, Leavitt BR, Cattaneo E, Ferrante RJ, Hayden MR, Friedlander RM. Depletion of wild-type huntingtin in mouse models of neurologic diseases. Journal of Neurochemistry. 87: 101-6. PMID 12969257 DOI: 10.1046/J.1471-4159.2003.01980.X  0.394
2003 Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dodé C, Morrison PJ, Suchowersky O, Ross CA, Margolis RL, Rosenblatt A, Gómez-Tortosa E, Cabrero DM, Novelletto A, Frontali M, et al. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. American Journal of Human Genetics. 73: 682-7. PMID 12900792 DOI: 10.1086/378133  0.649
2003 Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron. 39: 227-39. PMID 12873381 DOI: 10.1016/S0896-6273(03)00366-0  0.305
2003 Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human Molecular Genetics. 12: 1555-67. PMID 12812983 DOI: 10.1093/Hmg/Ddg169  0.837
2003 Creighton S, Almqvist EW, MacGregor D, Fernandez B, Hogg H, Beis J, Welch JP, Riddell C, Lokkesmoe R, Khalifa M, MacKenzie J, Sajoo A, Farrell S, Robert F, Shugar A, ... ... Hayden MR, et al. Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clinical Genetics. 63: 462-75. PMID 12786753 DOI: 10.1034/J.1399-0004.2003.00093.X  0.346
2003 Djoussé L, Knowlton B, Hayden M, Almqvist EW, Brinkman R, Ross C, Margolis R, Rosenblatt A, Durr A, Dode C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, McCusker E, et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. American Journal of Medical Genetics. Part A. 119: 279-82. PMID 12784292 DOI: 10.1002/Ajmg.A.20190  0.658
2003 Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Lévi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain : a Journal of Neurology. 126: 946-55. PMID 12615650 DOI: 10.1093/Brain/Awg077  0.304
2003 Wellington CL, Ellerby LM, Leavitt BR, Roy S, Nicholson DW, Hayden MR. Huntington proteolysis in Huntington disease Clinical Neuroscience Research. 3: 129-139. DOI: 10.1016/S1566-2772(03)00055-0  0.391
2002 Wellington CL, Yang YZ, Zhou S, Clee SM, Tan B, Hirano K, Zwarts K, Kwok A, Gelfer A, Marcil M, Newman S, Roomp K, Singaraja R, Collins J, Zhang LH, ... ... Hayden MR, et al. Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. Journal of Lipid Research. 43: 1939-49. PMID 12401893 DOI: 10.1194/Jlr.M200277-Jlr200  0.641
2002 Singaraja RR, Hadano S, Metzler M, Givan S, Wellington CL, Warby S, Yanai A, Gutekunst CA, Leavitt BR, Yi H, Fichter K, Gan L, McCutcheon K, Chopra V, Michel J, ... ... Hayden MR, et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Human Molecular Genetics. 11: 2815-28. PMID 12393793 DOI: 10.1093/Hmg/11.23.2815  0.354
2002 Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, ... ... Hayden MR, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 7862-72. PMID 12223539 DOI: 10.1523/Jneurosci.22-18-07862.2002  0.836
2002 Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Human Molecular Genetics. 11: 1939-51. PMID 12165556 DOI: 10.1093/Hmg/11.17.1939  0.336
2002 Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart JC, McManus BM, Staels B, Hayden MR. Increased ABCA1 activity protects against atherosclerosis. The Journal of Clinical Investigation. 110: 35-42. PMID 12093886 DOI: 10.1172/Jci15748  0.638
2002 Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience. 5: 731-6. PMID 12089530 DOI: 10.1038/Nn884  0.332
2002 Zwarts KY, Clee SM, Zwinderman AH, Engert JC, Singaraja R, Loubser O, James E, Roomp K, Hudson TJ, Jukema JW, Kastelein JJ, Hayden MR. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clinical Genetics. 61: 115-25. PMID 11940086 DOI: 10.1034/J.1399-0004.2002.610206.X  0.641
2002 van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, Zwinderman AH, Smit AJ, Smelt AH, Groen AK, Hayden MR, Kastelein JJ. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet (London, England). 359: 37-42. PMID 11809185 DOI: 10.1016/S0140-6736(02)07277-X  0.636
2002 Gervais FG, Singaraja R, Xanthoudakis S, Gutekunst CA, Leavitt BR, Metzler M, Hackam AS, Tam J, Vaillancourt JP, Houtzager V, Rasper DM, Roy S, Hayden MR, Nicholson DW. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nature Cell Biology. 4: 95-105. PMID 11788820 DOI: 10.1038/Ncb735  0.308
2001 Cepeda C, Ariano MA, Calvert CR, Flores-Hernández J, Chandler SH, Leavitt BR, Hayden MR, Levine MS. NMDA receptor function in mouse models of Huntington disease. Journal of Neuroscience Research. 66: 525-39. PMID 11746372 DOI: 10.1002/Jnr.1244  0.331
2001 Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clinical Genetics. 60: 293-300. PMID 11683775 DOI: 10.1034/J.1399-0004.2001.600407.X  0.635
2001 Almqvist EW, Elterman DS, MacLeod PM, Hayden MR. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia Clinical Genetics. 60: 198-205. PMID 11595021 DOI: 10.1034/J.1399-0004.2001.600305.X  0.375
2001 Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 57: 658-62. PMID 11524475 DOI: 10.1212/Wnl.57.4.658  0.635
2001 Rosenblatt A, Brinkman RR, Liang KY, Almqvist EW, Margolis RL, Huang CY, Sherr M, Franz ML, Abbott MH, Hayden MR, Ross CA. Familial influence on age of onset among siblings with Huntington disease. American Journal of Medical Genetics. 105: 399-403. PMID 11449389 DOI: 10.1002/Ajmg.1400  0.576
2001 Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, Tan B, Brooks-Wilson A, Kwok A, Bissada N, Yang YZ, Liu G, Tafuri SR, Fievet C, Wellington CL, ... ... Hayden MR, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. The Journal of Biological Chemistry. 276: 33969-79. PMID 11423537 DOI: 10.1074/Jbc.M102503200  0.651
2001 Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (New York, N.Y.). 293: 493-8. PMID 11408619 DOI: 10.1126/Science.1059581  0.307
2001 McGladdery SH, Pimstone SN, Clee SM, Bowden JF, Hayden MR, Frohlich JJ. Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population. Atherosclerosis. 156: 401-7. PMID 11395037 DOI: 10.1016/S0021-9150(00)00670-5  0.63
2001 Otto CJ, Almqvist E, Hayden MR, Andrew SE. The "flap" endonuclease gene FEN1 is excluded as a candidate gene implicated in the CAG repeat expansion underlying Huntington disease. Clinical Genetics. 59: 122-7. PMID 11260214 DOI: 10.1034/j.1399-0004.2001.590210.x  0.369
2001 Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K, Jukema JW, van Wijland M, van Dam M, Hudson TJ, Brooks-Wilson A, Genest J, Kastelein JJ, Hayden MR. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation. 103: 1198-205. PMID 11238261 DOI: 10.1161/01.Cir.103.9.1198  0.633
2001 Falush D, Almqvist EW, Brinkmann RR, Iwasa Y, Hayden MR. Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. American Journal of Human Genetics. 68: 373-85. PMID 11225602 DOI: 10.1086/318193  0.331
2001 Backus RC, Ginzinger DG, Ashbourne Excoffon KJ, Clee SM, Hayden MR, Eckel RH, Hickman MA, Rogers QR. Maternal expression of functional lipoprotein lipase and effects on body fat mass and body condition scores of mature cats with lipoprotein lipase deficiency. American Journal of Veterinary Research. 62: 264-9. PMID 11212037 DOI: 10.2460/Ajvr.2001.62.264  0.606
2001 Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden MR, Margolis RL, Ross CA, Dausset J, Ferrante RJ, Néri C. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 98: 1811-6. PMID 11172033 DOI: 10.1073/Pnas.98.4.1811  0.364
2001 Zeron MM, Chen N, Moshaver A, Lee AT, Wellington CL, Hayden MR, Raymond LA. Mutant huntingtin enhances excitotoxic cell death. Molecular and Cellular Neurosciences. 17: 41-53. PMID 11161468 DOI: 10.1006/Mcne.2000.0909  0.31
2001 Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. American Journal of Human Genetics. 68: 313-24. PMID 11133364 DOI: 10.1086/318207  0.317
2000 Wellington CL, Leavitt BR, Hayden MR. Huntington disease: new insights on the role of huntingtin cleavage. Journal of Neural Transmission. Supplementum. 1-17. PMID 11128600 DOI: 10.1007/978-3-7091-6284-2_1  0.357
2000 Clee SM, Kastelein JJ, van Dam M, Marcil M, Roomp K, Zwarts KY, Collins JA, Roelants R, Tamasawa N, Stulc T, Suda T, Ceska R, Boucher B, Rondeau C, DeSouich C, ... ... Hayden MR, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. The Journal of Clinical Investigation. 106: 1263-70. PMID 11086027 DOI: 10.1172/Jci10727  0.648
2000 Hayden MR, Clee SM, Brooks-Wilson A, Genest J, Attie A, Kastelein JJ. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Current Opinion in Lipidology. 11: 117-22. PMID 10787172 DOI: 10.1097/00041433-200004000-00003  0.633
2000 Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, Nicholson DW, Bredesen DE, Hayden MR. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. The Journal of Biological Chemistry. 275: 19831-8. PMID 10770929 DOI: 10.1074/Jbc.M001475200  0.339
2000 Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, Steures P, McManus J, McManus B, LeBoeuf RC, Kastelein JJ, Hayden MR. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. Journal of Lipid Research. 41: 521-31. PMID 10744772  0.648
1999 Leavitt BR, Wellington CL, Hayden MR. Recent insights into the molecular pathogenesis of Huntington disease. Seminars in Neurology. 19: 385-95. PMID 10716661 DOI: 10.1055/S-2008-1040853  0.39
1999 Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, Yu L, Collins JA, van Dam M, Molhuizen HO, Loubster O, Ouellette BF, Sensen CW, Fichter K, Mott S, Denis M, ... ... Hayden MR, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 354: 1341-6. PMID 10533863 DOI: 10.1016/S0140-6736(99)07026-9  0.64
1999 Hackam AS, Hodgson JG, Singaraja R, Zhang T, Gan L, Gutekunst CA, Hersch SM, Hayden MR. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 1047-55. PMID 10434304 DOI: 10.1098/Rstb.1999.0457  0.32
1999 Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, ... ... Hayden MR, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genetics. 22: 336-45. PMID 10431236 DOI: 10.1038/11905  0.648
1999 Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, ... ... Hayden MR, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23: 181-92. PMID 10402204 DOI: 10.1016/S0896-6273(00)80764-3  0.339
1999 Almqvist EW, Bloch M, Brinkman R, Craufurd D, Hayden MR. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. American Journal of Human Genetics. 64: 1293-304. PMID 10205260 DOI: 10.1086/302374  0.564
1999 Ginzinger DG, Clee SM, Dallongeville J, Lewis ME, Henderson HE, Bauje E, Rogers QR, Jensen DR, Eckel RH, Dyer R, Innis S, Jones B, Fruchart JC, Hayden MR. Lipid and lipoprotein analysis of cats with lipoprotein lipase deficiency. European Journal of Clinical Investigation. 29: 17-26. PMID 10092984 DOI: 10.1046/j.1365-2362.1999.00435.x  0.626
1999 O'Kusky JR, Nasir J, Cicchetti F, Parent A, Hayden MR. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. Brain Research. 818: 468-79. PMID 10082833 DOI: 10.1016/S0006-8993(98)01312-2  0.303
1999 Metzler M, Chen N, Helgason CD, Graham RK, Nichol K, McCutcheon K, Nasir J, Humphries RK, Raymond LA, Hayden MR. Life without huntingtin: normal differentiation into functional neurons. Journal of Neurochemistry. 72: 1009-18. PMID 10037472 DOI: 10.1046/J.1471-4159.1999.0721009.X  0.687
1999 Hadano S, Nichol K, Brinkman RR, Nasir J, Martindale D, Koop BF, Nicholson DW, Scherer SW, Ikeda JE, Hayden MR. A yeast artificial chromosome-based physical map of the juvenile amyotrophic lateral sclerosis (ALS2) critical region on human chromosome 2q33-q34. Genomics. 55: 106-12. PMID 9889004 DOI: 10.1006/Geno.1998.5637  0.514
1998 Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja R, Kazemi-Esfarjani P, Devon R, Kim SU, Bredesen DE, Tufaro F, Hayden MR. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates Nature Genetics. 18: 150-154. PMID 9462744 DOI: 10.1038/Ng0298-150  0.326
1997 Ehrenborg E, Clee SM, Pimstone SN, Reymer PW, Benlian P, Hoogendijk CF, Davis HJ, Bissada N, Miao L, Gagné SE, Greenberg LJ, Henry R, Henderson H, Ordovas JM, Schaefer EJ, ... ... Hayden MR, et al. Ethnic variation and in vivo effects of the -93t-->g promoter variant in the lipoprotein lipase gene. Arteriosclerosis, Thrombosis, and Vascular Biology. 17: 2672-8. PMID 9409241 DOI: 10.1161/01.Atv.17.11.2672  0.628
1997 Ginzinger DG, Wilson JE, Redenbach D, Lewis ME, Clee SM, Excoffon KJ, Rogers QR, Hayden MR, McManus BM. Diet-induced atherosclerosis in the domestic cat. Laboratory Investigation; a Journal of Technical Methods and Pathology. 77: 409-19. PMID 9389784  0.624
1997 Clee SM, Zhang H, Bissada N, Miao L, Ehrenborg E, Benlian P, Shen GX, Angel A, LeBoeuf RC, Hayden MR. Relationship between lipoprotein lipase and high density lipoprotein cholesterol in mice: modulation by cholesteryl ester transfer protein and dietary status. Journal of Lipid Research. 38: 2079-89. PMID 9374130  0.645
1997 Wellington CL, Hayden MR. Of molecular interactions, mice and mechanisms: New insights into Huntington's disease Current Opinion in Neurology. 10: 291-298. PMID 9266152 DOI: 10.1097/00019052-199708000-00003  0.371
1997 Wellington CL, Brinkman RR, O'Kusky JR, Hayden MR. Toward understanding the molecular pathology of Huntington's disease. Brain Pathology (Zurich, Switzerland). 7: 979-1002. PMID 9217979 DOI: 10.1111/J.1750-3639.1997.Tb00897.X  0.666
1997 Pimstone SN, Defesche JC, Clee SM, Bakker HD, Hayden MR, Kastelein JJ. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 17: 826-33. PMID 9157944 DOI: 10.1161/01.Atv.17.5.826  0.633
1997 Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. American Journal of Human Genetics. 60: 1202-10. PMID 9150168  0.643
1997 Kalchman MA, Koide HB, McCutcheon K, Graham RK, Nichol K, Nishiyama K, Kazemi-Esfarjani P, Lynn FC, Wellington C, Metzler M, Goldberg YP, Kanazawa I, Gietz RD, Hayden MR. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nature Genetics. 16: 44-53. PMID 9140394 DOI: 10.1038/ng0597-44  0.714
1997 Chong SS, Almqvist E, Telenius H, LaTray L, Nichol K, Bourdelat-Parks B, Goldberg YP, Haddad BR, Richards F, Sillence D, Greenberg CR, Ives E, Van Den Engh G, Hughes MR, Hayden MR. Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: Evidence from single sperm analyses Human Molecular Genetics. 6: 301-309. PMID 9063751 DOI: 10.1093/Hmg/6.2.301  0.309
1996 Hodgson JG, Smith DJ, McCutcheon K, Koide HB, Nishiyama K, Dinulos MB, Stevens ME, Bissada N, Nasir J, Kanazawa I, Disteche CM, Rubin EM, Hayden MR. Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype Human Molecular Genetics. 5: 1875-1885. PMID 8968738 DOI: 10.1093/Hmg/5.12.1875  0.367
1996 Nasir J, Goldberg YP, Hayden MR. Huntington disease: New insights into the relationship between CAG expansion and disease Human Molecular Genetics. 5: 1431-1435. PMID 8875248 DOI: 10.1093/Hmg/5.Supplement_1.1431  0.392
1996 Pimstone SN, Clee SM, Gagné SE, Miao L, Zhang H, Stein EA, Hayden MR. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers. Journal of Lipid Research. 37: 1675-84. PMID 8864951  0.635
1996 Goldberg YP, Kalchman MA, Metzler M, Nasir J, Zeisler J, Graham R, Koide HB, O'Kusky J, Sharp AH, Ross CA, Jirik F, Hayden MR. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript Human Molecular Genetics. 5: 177-185. PMID 8824873 DOI: 10.1093/Hmg/5.2.177  0.724
1996 Kalchman MA, Graham RK, Xia G, Brook Koide H, Graeme Hodgson J, Graham KC, Paul Goldberg Y, Dan Gietz R, Pickart CM, Hayden MR. Huntingtin is ubiquitinated and interacts with a specific ubiquitin- conjugating enzyme Journal of Biological Chemistry. 271: 19385-19394. PMID 8702625 DOI: 10.1074/Jbc.271.32.19385  0.688
1996 Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, Hayden MR. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genetics. 13: 442-9. PMID 8696339 DOI: 10.1038/Ng0896-442  0.598
1996 Zhang H, Henderson H, Gagne SE, Clee SM, Miao L, Liu G, Hayden MR. Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Biochimica Et Biophysica Acta. 1302: 159-66. PMID 8695666 DOI: 10.1016/0005-2760(96)00059-8  0.631
1995 Andrew SE, Hayden MR. Origins and evolution of huntington disease chromosomes Neurodegeneration. 4: 239-244. PMID 8581556 DOI: 10.1016/1055-8330(95)90013-6  0.35
1995 Lin B, Nasir J, McDonald H, Graham R, Rommens JM, Goldberg YP, Hayden MR. Genomic organization of the human alpha-adducin gene and its alternately spliced isoforms. Genomics. 25: 93-9. PMID 7774961 DOI: 10.1016/0888-7543(95)80113-Z  0.598
1995 Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, Hayden MR. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 81: 811-23. PMID 7774020 DOI: 10.1016/0092-8674(95)90542-1  0.376
1995 Almqvist E, Spence N, Nichol K, Andrew SE, Vesa J, Peltonen L, Anvret M, Goto J, Kanazawa I, Goldberg YP, Hayden MR. Ancestral differences in the distribution of the Δ2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease Human Molecular Genetics. 4: 207-214. PMID 7757069 DOI: 10.1093/Hmg/4.2.207  0.305
1994 Riess O, Thies U, Siedlaczck I, Potisek S, Graham R, Theilmann J, Grimm T, Epplen JT, Hayden MR. Precise mapping of the brain alpha 2-adrenergic receptor gene within chromosome 4p16. Genomics. 19: 298-302. PMID 8188260 DOI: 10.1006/Geno.1994.1061  0.685
1994 Lin B, Nasir J, MacDonald H, Hutchinson G, Graham RK, Rommens JM, Hayden MR. Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat [corrected]. Human Molecular Genetics. 3: 85-92. PMID 8162057 DOI: 10.1093/Hmg/3.1.85  0.598
1994 Almqvist E, Andrew S, Theilmann J, Goldberg P, Zeisler J, Drugge U, Grandell U, Tapper-Persson M, Winblad B, Hayden M, Anvret M. Geographical distribution of haplotypes in Swedish families with Huntington's disease. Human Genetics. 94: 124-128. PMID 8045558 DOI: 10.1007/Bf00202856  0.372
1994 Goldberg YP, Telenius H, Hayden MR. The molecular genetics of Huntington's disease Current Opinion in Neurology. 7: 325-332. PMID 7952241  0.386
1994 Lin B, Rommens JM, Graham RK, Kalchman M, MacDonald H, Nasir J, Delaney A, Goldberg YP, Hayden MR. Differential 3' polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. Human Molecular Genetics. 2: 1541-5. PMID 7903579 DOI: 10.1093/Hmg/2.10.1541  0.598
1994 Squitieri F, Andrew SE, Goldberg YP, Kremer B, Spence N, Zelsler J, Nichol K, Theilmann J, Greenberg J, Goto J, Kanazawa I, Vesa J, Peltonen L, Almqvist E, Anvret M, ... ... Hayden MR, et al. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence Human Molecular Genetics. 3: 2103-2114. PMID 7881406 DOI: 10.1093/Hmg/3.12.2103  0.348
1994 Weber B, Riess O, Wolff G, Andrew S, Collins C, Graham R, Theilmann J, Hayden MR. Delineation of a 50 kilobase DNA segment containing the recombination site in a sporadic case of Huntington's disease. Nature Genetics. 2: 216-22. PMID 1345172 DOI: 10.1038/Ng1192-216  0.598
1994 Lin B, Nasir J, MacDonald H, Hutchinson G, Graham R, Rommens J, Hayden M. Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat Human Molecular Genetics. 3: 530-530. DOI: 10.1093/Hmg/3.3.530-A  0.709
1993 Collins C, Duff C, Duncan AM, Planells-Cases R, Sun W, Norremolle A, Michaelis E, Montal M, Worton R, Hayden MR. Mapping of the human NMDA receptor subunit (NMDAR1) and the proposed NMDA receptor glutamate-binding subunit (NMDARA1) to chromosomes 9q34.3 and chromosome 8, respectively. Genomics. 17: 237-9. PMID 8406459 DOI: 10.1006/Geno.1993.1311  0.313
1993 Weber B, Riess O, Daneshvar H, Graham R, Hayden MR. (CA)n-dinucleotide repeat at the PDEB locus in 4p16.3. Human Molecular Genetics. 2: 827. PMID 8394765 DOI: 10.1093/Hmg/2.6.827  0.598
1993 Hutchinson GB, Andrew SE, McDonald H, Goldberg YP, Graham R, Rommens JM, Hayden MR. An Alu element retroposition in two families with Huntington disease defines a new active Alu subfamily. Nucleic Acids Research. 21: 3379-83. PMID 8393987 DOI: 10.1093/Nar/21.15.3379  0.598
1993 Andrew S, Theilmann J, Almqvist E, Norremolle A, Lucotte G, Anvret M, Sorensen SA, Turpin JC, Hayden MR. DNA analysis of distinct populations suggests multiple origins for the mutation causing Huntington disease. Clinical Genetics. 43: 286-94. PMID 8370147 DOI: 10.1111/J.1399-0004.1993.Tb03820.X  0.325
1992 Goldberg YP, Lin B-, Andrew SE, Nasir J, Graham R, Glaves ML, Hutchinson G, Theilmann J, Ginzinger DG, Schappert K, Clarke L, Rommens JM, Hayden MR. Cloning and mapping of the α-adducin gene close to D4S95 and assessment of its relationship to Huntington disease Human Molecular Genetics. 1: 669-675. PMID 1284592 DOI: 10.1093/Hmg/1.9.669  0.699
1989 Fahy M, Robbins C, Bloch M, Turnell RW, Hayden MR. Different options for prenatal testing for Huntington's disease using DNA probes Journal of Medical Genetics. 26: 353-357. PMID 2525622 DOI: 10.1136/Jmg.26.6.353  0.342
1988 Wasmuth JJ, Hewitt J, Smith B, Allard D, Haines JL, Skarecky D, Partlow E, Hayden MR. A highly polymorphic locus very tightly linked to the Huntington's disease gene Nature. 332: 734-736. PMID 3386718 DOI: 10.1038/332734A0  0.357
1988 Jason GW, Pajurkova EM, Suchowersky O, Hewitt J, Hilbert C, Reed J, Hayden MR. Presymptomatic neuropsychological impairment in Huntington's disease. Archives of Neurology. 45: 769-73. PMID 2968784 DOI: 10.1001/Archneur.1988.00520310079021  0.353
1986 Suchowersky O, Hayden MR, Martin WR, Stoessl AJ, Hildebrand AM, Pate BD. Cerebral metabolism of glucose in benign hereditary chorea. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 33-44. PMID 2973557 DOI: 10.1002/Mds.870010105  0.319
Show low-probability matches.